These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 27452651)
1. Answer to the review from Halstead and Russell "Protective and immunological behavior of chimeric yellow fever dengue vaccine" (DOI 10.1016/j.vaccine.2016.02.004). Hadinegoro SR; Arredondo-García JL; Guy B; Bouckenooghe A; Noriega F; Jackson N Vaccine; 2016 Aug; 34(36):4273-4. PubMed ID: 27452651 [No Abstract] [Full Text] [Related]
2. Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Liang H; Lee M; Jin X Cell Mol Immunol; 2016 Jan; 13(1):36-46. PubMed ID: 26435066 [TBL] [Abstract][Full Text] [Related]
3. Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-α and IFN-α profiles. Gandini M; Reis SR; Torrentes-Carvalho A; Azeredo EL; Freire Mda S; Galler R; Kubelka CF Mem Inst Oswaldo Cruz; 2011 Aug; 106(5):594-605. PubMed ID: 21894381 [TBL] [Abstract][Full Text] [Related]
4. Vaccines licensed and in clinical trials for the prevention of dengue. Torresi J; Ebert G; Pellegrini M Hum Vaccin Immunother; 2017 May; 13(5):1059-1072. PubMed ID: 28281864 [TBL] [Abstract][Full Text] [Related]
5. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226 [TBL] [Abstract][Full Text] [Related]
6. Dengue and yellow fever--challenges for the development and use of vaccines. Monath TP N Engl J Med; 2007 Nov; 357(22):2222-5. PubMed ID: 18046026 [No Abstract] [Full Text] [Related]
7. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4. Deauvieau F; Sanchez V; Balas C; Kennel A; DE Montfort A; Lang J; Guy B Am J Trop Med Hyg; 2007 Jan; 76(1):144-54. PubMed ID: 17255244 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults. Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510 [TBL] [Abstract][Full Text] [Related]
9. Measurement of Cellular Immune Response to Viral Infection and Vaccination. Bouwman W; Verhaegh W; Holtzer L; van de Stolpe A Front Immunol; 2020; 11():575074. PubMed ID: 33193365 [TBL] [Abstract][Full Text] [Related]
10. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Halstead SB; Russell PK Vaccine; 2016 Mar; 34(14):1643-7. PubMed ID: 26873054 [TBL] [Abstract][Full Text] [Related]
11. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. McGee CE; Lewis MG; Claire MS; Wagner W; Lang J; Guy B; Tsetsarkin K; Higgs S; Decelle T J Infect Dis; 2008 Mar; 197(5):693-7. PubMed ID: 18266603 [TBL] [Abstract][Full Text] [Related]
13. Current status, challenges and perspectives in the development of vaccines against yellow fever, dengue, Zika and chikungunya viruses. Silva JVJ; Lopes TRR; Oliveira-Filho EF; Oliveira RAS; Durães-Carvalho R; Gil LHVG Acta Trop; 2018 Jun; 182():257-263. PubMed ID: 29551394 [TBL] [Abstract][Full Text] [Related]
14. [Serologic survey for yellow fever and other arboviruses among inhabitants of Rio Branco, Brazil, before and three months after receiving the yellow fever 17D vaccine]. Tavares-Neto J; Freitas-Carvalho J; Nunes MR; Rocha G; Rodrigues SG; Damasceno E; Darub R; Viana S; Vasconcelos PF Rev Soc Bras Med Trop; 2004; 37(1):1-6. PubMed ID: 15042172 [TBL] [Abstract][Full Text] [Related]
15. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. Mantel N; Aguirre M; Gulia S; Girerd-Chambaz Y; Colombani S; Moste C; Barban V J Virol Methods; 2008 Jul; 151(1):40-6. PubMed ID: 18501437 [TBL] [Abstract][Full Text] [Related]
16. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Guy B; Jackson N Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777 [TBL] [Abstract][Full Text] [Related]
17. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Barrett AD; Teuwen DE Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559 [TBL] [Abstract][Full Text] [Related]
18. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease. Barrett ADT Vaccine; 2017 Oct; 35(44):5951-5955. PubMed ID: 28366605 [TBL] [Abstract][Full Text] [Related]
19. Review of dengue virus and the development of a vaccine. Murrell S; Wu SC; Butler M Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601 [TBL] [Abstract][Full Text] [Related]
20. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. Brandriss MW; Schlesinger JJ; Walsh EE; Briselli M J Gen Virol; 1986 Feb; 67 ( Pt 2)():229-34. PubMed ID: 3944585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]